258 related articles for article (PubMed ID: 25496075)
21. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
[TBL] [Abstract][Full Text] [Related]
22. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer.
Bang JI; Ha S; Kang SB; Lee KW; Lee HS; Kim JS; Oh HK; Lee HY; Kim SE
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):422-31. PubMed ID: 26338180
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
25. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
26. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA
Breast J; 2006; 12(2):159-64. PubMed ID: 16509842
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
[TBL] [Abstract][Full Text] [Related]
28. Early predictive value of non-response to docetaxel in neoadjuvant chemotherapy in breast cancer using 18F-FDG-PET.
Hirakata T; Yanagita Y; Fujisawa T; Fujii T; Kinoshita T; Horikoshi H; Oya N; Akiyoshi T; Iijima M; Miyamoto T; Kuwano H
Anticancer Res; 2014 Jan; 34(1):221-6. PubMed ID: 24403466
[TBL] [Abstract][Full Text] [Related]
29. Role of
Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
31. JOURNAL CLUB: Value of Quantitative FDG PET/CT Volumetric Biomarkers in Recurrent Colorectal Cancer Patient Survival.
Marcus C; Wray R; Taghipour M; Marashdeh W; Ahn SJ; Mena E; Subramaniam RM
AJR Am J Roentgenol; 2016 Aug; 207(2):257-65. PubMed ID: 27447341
[TBL] [Abstract][Full Text] [Related]
32. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
33. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Hortobagyi GN; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Buchholz TA
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):351-7. PubMed ID: 15890574
[TBL] [Abstract][Full Text] [Related]
34. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
35. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
36. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
Li SP; Makris A; Beresford MJ; Taylor NJ; Ah-See ML; Stirling JJ; d'Arcy JA; Collins DJ; Kozarski R; Padhani AR
Radiology; 2011 Jul; 260(1):68-78. PubMed ID: 21502383
[TBL] [Abstract][Full Text] [Related]
37. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
J Clin Oncol; 2004 Dec; 22(23):4691-9. PubMed ID: 15570071
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
[TBL] [Abstract][Full Text] [Related]
39. ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.
Tani Y; Nakajima M; Kikuchi M; Ihara K; Muroi H; Takahashi M; Domeki Y; Okamoto K; Yamaguchi S; Sasaki K; Tsuchioka T; Sakamoto S; Kato H
Anticancer Res; 2016 Jan; 36(1):367-73. PubMed ID: 26722067
[TBL] [Abstract][Full Text] [Related]
40. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis.
Mghanga FP; Lan X; Bakari KH; Li C; Zhang Y
Clin Breast Cancer; 2013 Aug; 13(4):271-9. PubMed ID: 23714689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
